Gastroenterology and Liver Services, Sydney South West Area Health Service, Concord Hospital, Concord, Sydney, New South Wales, Australia.
J Gastroenterol Hepatol. 2009 Jun;24(6):1098-101. doi: 10.1111/j.1440-1746.2009.05802.x.
Percutaneous endoscopic gastrostomy (PEG) provides enteral nutrition to patients who cannot swallow. Few studies have prospectively evaluated its long-term outcomes or eventual resumption of oral intake.
Consecutive PEG patients were prospectively recruited from a tertiary hospital over 12 months and followed until all had met the primary endpoints of death or resumption of oral diet with PEG extubation. Data was collected by standardised periodic phone interview.
Forty patients (24 males, median age 74 years) were followed for up to 8.4 years (median 5.3 months, interquartile range [IQR] 13.6 months). The end-of-study mortality rate was 70% (median 6.8 months, IQR 19.9 months) and the only predictor of mortality was head injury as the indication for PEG (Cox regression HR 5.90, 95% CI: 1.2-28.4). At two years following PEG, 30% of patients had resumed oral intake (median 2.9 months, IQR 7.2 months) and 19% remained on PEG-feeding. Predictors of resumption of oral intake were the ability to tolerate some oral intake at 3 months (HR: 248.5, 95% CI: 8.7-7065.3) and 6 months (HR: 6.3, 95% CI: 1.03-38.9) but not at 12 months. Cumulative survival was highest for ear nose and throat (ENT) tumour and worst for acute head injury (log rank P = 0.048).
Half of all PEG patients remained alive at 2 years using PEG or have resumed full oral intake. A supervised trial of oral intake at 3 or 6 months may help predict eventual resumption of per oral diet.
经皮内镜胃造口术(PEG)为无法吞咽的患者提供肠内营养。很少有研究前瞻性评估其长期结果或最终恢复口服摄入。
在 12 个月内,连续从一家三级医院招募 PEG 患者进行前瞻性研究,并随访至所有患者达到主要终点,即死亡或拔除 PEG 后恢复口服饮食。通过标准定期电话访谈收集数据。
40 例患者(24 例男性,中位年龄 74 岁)随访时间最长达 8.4 年(中位随访时间为 5.3 个月,四分位间距 [IQR] 13.6 个月)。研究结束时的死亡率为 70%(中位时间为 6.8 个月,IQR 为 19.9 个月),死亡率的唯一预测因素是头部受伤作为 PEG 的适应证(Cox 回归 HR 5.90,95%CI:1.2-28.4)。在 PEG 后两年,30%的患者恢复了口服摄入(中位时间为 2.9 个月,IQR 为 7.2 个月),19%的患者仍在接受 PEG 喂养。恢复口服摄入的预测因素是在 3 个月(HR:248.5,95%CI:8.7-7065.3)和 6 个月(HR:6.3,95%CI:1.03-38.9)时能够耐受一些口服摄入,但 12 个月时不能。累积生存率最高的是耳鼻喉肿瘤,最差的是急性头部受伤(对数秩 P = 0.048)。
所有 PEG 患者中有一半在 2 年内通过 PEG 仍存活或已恢复完全口服摄入。在 3 或 6 个月时进行口服摄入的监督试验可能有助于预测最终恢复口服饮食。